AbbVie Inc (NYSE:ABBV) shares are sliding on Thursday after the company cut its fourth‑quarter and full‑year 2025 guidance, was downgraded by Wolfe Research and pushed back on reports that it's pursuing a major acquisition.
What Happened: AbbVie said it now expects to take a $1.3 billion charge for acquired IPR&D and milestone expenses in the fourth-quarter of 2025. That will reduce adjusted earnings by 71 cents per share.
The company now sees 2025 adjusted EPS at $9.90 to $9.94, and fourth‑quarter adjusted EPS at $2.61 to $2.65.
The company noted that its earlier Oct. 31 guidance did not include potential IPR&D or milestone expenses beyond the third-quarter, and added that its year‑end results are still being finalized. The company mentioned that results for the quarter ended Dec. 31, 2025 have not yet been finalized.
Wolfe Research analyst Alexandria Hammond also downgraded the stock from Outperform to Peer Perform, adding to the downward momentum.
ABBV Price Action: AbbVie shares were down 3.97% at $224.17 at the time of publication on Thursday, according to Benzinga Pro.
Read Next:
Image: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
